Daysha Ferrer-Torres

Dr. Daysha Ferrer-Torres

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2019 in Gastroenterology
Verified
Journal Article
Closed access
DRDipankar Ray
Dipankar Ray
PRParamita Ray
Paramita Ray
DFDaysha Ferrer-Torres
Daysha Ferrer-Torres
ZWZhuwen Wang
Zhuwen Wang
DNDerek Nancarrow
Derek Nancarrow
DBDavid G. Beer
David G. Beer

15 October 2022 in Development
Verified
Journal Article
Open access
PDF file
DFDaysha Ferrer-Torres
Daysha Ferrer-Torres
JWJoshua H. Wu
Joshua H. Wu
CZCharles J. Zhang
Charles J. Zhang
MHMax A. Hammer
Max A. Hammer
MDMichael Dame
Michael Dame
JSJason R. Spence
Jason R. Spence
Many esophageal diseases can arise during development or throughout life. Therefore, well-characterized in vitro models and detailed methods are essential for studying human esophageal development, homeostasis and disease. Here, we (1) create an atlas of the cell types observed in the normal adult human esophagus; (2) establish an ancestrally diverse biobank of in vitro esophagus tissue to interrogate homeostasis and injury; and (3) benchmark in vitro models using the adult human esophagus atlas. We created a single-cell RNA sequencing reference atlas using fresh adult esophagus biopsies and a continuously expanding biobank of patient-derived in vitro cultures (n=55 lines). We identify and validate several transcriptionally distinct cell classes in the native human adult esophagus, with four populations belonging to the epithelial layer, including basal, epibasal, early differentiating and terminally differentiated luminal cells. Benchmarking in vitro esophagus cultures to the in vivo reference using single-cell RNA sequencing shows that the basal stem cells are robustly maintained in vitro, and the diversity of epithelial cell types in culture is dependent on cell density. We also demonstrate that cultures can be grown in 2D or as 3D organoids, and these methods can be employed for modeling the complete epithelial layers, thereby enabling in vitro modeling of the human adult esophagus.

28 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
CZCharles J. Zhang
Charles J. Zhang
SMSophia R. Meyer
Sophia R. Meyer
MOMatthew James O'Meara
Matthew James O'Meara
SHSha Huang
Sha Huang
MCMeghan M. Capeling
Meghan M. Capeling
JSJonathan Z. Sexton
Jonathan Z. Sexton
Background and Aims: Drug-induced liver injury (DILI), both intrinsic and idiosyncratic, causes frequent morbidity, mortality, clinical trial failures and post-approval withdrawal. This suggests an unmet need for improved in vitro models for DILI risk prediction that can account for diverse host genetics and other clinical factors. In this study, we evaluated the utility of human liver organoids (HLOs) for high-throughput DILI risk prediction and in an organ-on-chip system. Methods: HLOs were derived from 3 separate iPSC lines and benchmarked on two platforms for their ability to model in vitro liver function and identify hepatotoxic compounds using biochemical assays for albumin, ALT, and AST, microscopy-based morphological profiling, and single-cell transcriptomics: 1) HLOs dispersed in 384-well formatted plates and exposed to a library of compounds. 2) HLOs adapted to a liver-on-chip system. Results: Dispersed HLOs derived from the 3 iPSC lines had similar DILI predictive capacity to intact HLOs in a high-throughput screening format allowing for measurable IC50 values of compound cytotoxicity. Distinct morphological differences were observed in cells treated with drugs exerting differing mechanisms of toxicity. On-chip HLOs significantly increased albumin production, CYP450 expression, and ALT/AST release when treated with known DILI drugs compared to dispersed HLOs and primary human hepatocytes. On-chip HLOs were able to predict the synergistic hepatotoxicity of tenofovir-inarigivir and showed steatosis and mitochondrial perturbation via phenotypic and transcriptomic analysis with exposure to FIAU and acetaminophen, respectively. Conclusions: The high throughput and liver-on-chip system exhibit enhanced in vivo -like function and demonstrate the potential utility of these platforms for hepatotoxicity risk assessment. Tenofovir-inarigivr associated hepatotoxicity was observed and correlates with the clinical manifestation of DILI observed in patients. LAY SUMMARY: Idiosyncratic (spontaneous, patient-specific) drug-induced liver injury (DILI) is difficult to study due to the lack of liver models that function as human liver tissue and are adaptable for large-scale drug screening. Human liver organoids grown from patient stem cells respond to known DILI-causing drugs in both a high-throughput and on a physiological “chip” culture system. These platforms show promise in their use as predictive model for novel drugs before entering clinical trials.

17 July 2024 in Molecular Cancer Research
Verified
Journal Article
Closed access
PRParamita Ray
Paramita Ray
SJSangeeta Jaiswal
Sangeeta Jaiswal
DFDaysha Ferrer-Torres
Daysha Ferrer-Torres
ZWZhuwen Wang
Zhuwen Wang
DNDerek Nancarrow
Derek Nancarrow
DRDipankar Ray
Dipankar Ray
Frequent (>70%) TP53 mutations often promote its protein stabilization, driving esophageal adenocarcinoma (EAC) development linked to poor survival and therapy resistance. We previously reported that during Barrett’s esophagus progression to EAC, an isoform switch occurs in the E3 ubiquitin ligase RNF128 (aka GRAIL—gene related to anergy in lymphocytes), enriching isoform 1 (hereby GRAIL1) and stabilizing the mutant p53 protein. Consequently, GRAIL1 knockdown degrades mutant p53. But, how GRAIL1 stabilizes the mutant p53 protein remains unclear. In search for a mechanism, here, we performed biochemical and cell biology studies to identify that GRAIL has a binding domain (315-PMCKCDILKA-325) for heat shock protein 40/DNAJ. This interaction can influence DNAJ chaperone activity to modulate misfolded mutant p53 stability. As predicted, either the overexpression of a GRAIL fragment (Frag-J) encompassing the DNAJ binding domain or a cell-permeable peptide (Pep-J) encoding the above 10 amino acids can bind and inhibit DNAJ-Hsp70 co-chaperone activity, thus degrading misfolded mutant p53. Consequently, either Frag-J or Pep-J can reduce the survival of mutant p53 containing dysplastic Barrett’s esophagus and EAC cells and inhibit the growth of patient-derived organoids of dysplastic Barrett’s esophagus in 3D cultures. The misfolded mutant p53 targeting and growth inhibitory effects of Pep-J are comparable with simvastatin, a cholesterol-lowering drug that can degrade misfolded mutant p53 also via inhibiting DNAJA1, although by a distinct mechanism. Implications: We identified a novel ubiquitin ligase-independent, chaperone-regulating domain in GRAIL and further synthesized a first-in-class novel misfolded mutant p53 degrading peptide having future translational potential.

17 June 2026
Verified
Other
Open access
PDF file
PRParamita Ray
Paramita Ray
SJSangeeta Jaiswal
Sangeeta Jaiswal
DFDaysha Ferrer-Torres
Daysha Ferrer-Torres
ZWZhuwen Wang
Zhuwen Wang
DNDerek Nancarrow
Derek Nancarrow
DRDipankar Ray
Dipankar Ray
Supplementary Figure S7. Design and testing of scrambled peptides as negative controls.

17 June 2026
Verified
Other
Open access
PRParamita Ray
Paramita Ray
SJSangeeta Jaiswal
Sangeeta Jaiswal
DFDaysha Ferrer-Torres
Daysha Ferrer-Torres
ZWZhuwen Wang
Zhuwen Wang
DNDerek Nancarrow
Derek Nancarrow
DRDipankar Ray
Dipankar Ray
Supplementary Figure S1. Purification of GRAIL1 C-terminal fragment.